Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest Articles(Click the title below to leave the MDLinx Network and go to the Journal's Website)
A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Clinical Cancer Research, 06/25/09
Goel S et al. - Eribulin mesylate, given on days 1, 8, and 15 of a 28-day cycle, exhibits manageable tolerability at 1.0 mg/m2 with further dose escalation limited by neutropenia and fatigue.
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Drug dosage protocol for calcium oxalate stone
Urological Research - Urolithiasis, 10/23/09
Risperidone dose for schizophrenia
Cochrane Reviews, 10/21/09
Pediatric antifungal agents
Current Opinion in Infectious Diseases, 10/28/09
Sponsor
Article Search
Sponsor